-
Area:
-
Land (surface area):
19,700 sq.m.
-
Plant (surface area):
7,700 sq.m.
VIANEX acquired Plant D from IFET (Institute of Pharmaceutical Research and Technology) in 1999. The company identified a need for an independent production unit for cephalosporin products, and this led to the plant’s initial operation in 2001 as one of the most sophisticated of the few units of this type operating in Europe at the time.
Plant D’s design principles were concerned with product safety, the minimisation of cephalosporin cross contamination, including at the final blister pack stage, employee health and safety, environmental protection and the implementation of current good manufacturing practices (cGMPs).
The plant’s continued full compliance with the latest requirements of Greek (EOF), European Legislation and global certification agencies, has ensured its ISO 9001:2000 certification. Many international pharmaceutical groups have entrusted VIANEX and Plant D with the exclusive production for export around the world.
PRODUCT CATEGORIES
Factory D prepares and packages the following products for both Greek and European markets:
- Dry suspensions
- Capsules
- Tablets
- Dry injectables
The active compounds which form the basis of the products are all 1st, 2nd, 3rd and 4th generation cephalosporins
PRODUCTION CAPACITY*
| DRY INJECTABLES | 10.000.000 vials |
| DRY SUSPENSIONS | 5.500.000 vials |
| CAPSULES | 65.000.000 |
| TABLETS | 250.000.000 |
| PACKAGING | 10.000.000 boxes |